WO2026125238 - COMPOSITIONS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/125238
Publication Date
18.06.2026
International Application No.
PCT/EP2025/085854
International Filing Date
08.12.2025
Title **
[English]
COMPOSITIONS AND METHODS OF USE THEREOF
[French]
COMPOSITIONS ET LEURS MÉTHODES D'UTILISATION
Applicants **
CAMURUS AB
Inventors
NISTOR, Catalin
JOHNSSON, Markus
TIBERG, Fredrik
Priority Data
2430648-2
10.12.2024
SE
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3126 | |
| EPO | Filing, Examination, Granting | 27490 | |
| Japan | Filing, Examination, Granting | 3266 | |
| South Korea | Filing, Examination, Granting | 4335 | |
| USA | Filing, Examination, Granting | 12140 |
Total:
50,357
Contact Us
Abstract[English]
This disclosure provides a lipid composition and methods of use thereof. This disclosure also provides a lipid composition comprising from about 5-150 mg retatrutide or an equivalent amount of a pharmaceutically acceptable salt thereof, as an active ingredient, one or more pharmaceutically acceptable lipid excipients, and one or more solvents[French]
La présente divulgation concerne une composition lipidique et ses méthodes d'utilisation. La présente divulgation concerne également une composition lipidique comprenant d'environ 5 à 150 mg de retatrutide ou une quantité équivalente d'un sel pharmaceutiquement acceptable de celui-ci, en tant que principe actif, un ou plusieurs excipients lipidiques pharmaceutiquement acceptables, et un ou plusieurs solvants.